Neola Medical

“A Major Milestone” – CEO Hanna Sjöström in interview with Life Science Sweden Neola Medical takes an important step forward in advancing neonatal care. After years of development, the company has received approval to initiate its first clinical study on preterm born babies—a key step in evaluating its continiuos lung monitoring device, Neola®, for this vulnerable patient group. In an interview with Life Science Sweden , CEO Hanna Sjöström discusses the significance of this milestone, what it means for the company, and how it supports Neola Medical’s strategy for entering the U.S. market, where Neola Medical sees significant potential for growth and impact in neonatal care. 💡 Read the full interview here:  https://lnkd.in/dTkDFjRC

🚀 Redeye Interview with CEO Hanna Sjöström Following the release of Neola Medical’s Q4 2024 report, Redeye Equity Research Analyst Gustaf Meyer interviewed CEO Hanna Sjöström to discuss key takeaways, the company’s progress toward the clinical phase, and the upcoming first clinical study on preterm born babies in Sweden 👶🇸🇪 🎥 Watch the full interview here: https://lnkd.in/dSi4X3jf Redeye AB also provided a research update, including a strengthened fair value range for Neola Medical. 💡Access the interview and additional insights from Redeye here: https://lnkd.in/dQd2n-rE

🌟 Did you miss Neola Medical’s Q4 report presentation? 🌟 Catch up on key insights into Neola Medical’s latest developments as we prepare for clinical studies and continue strengthening our presence in the U.S. market.🇺🇸 CEO Hanna Sjöström provides an update on key milestones and looks ahead as we enter the clinical phase och prepare for the first clinical study with Neola® in its target patient population, preterm born babies. CFO David Folkesson presents the financial results for 2024. 📊 🎥 Watch the full report and stay for the Q&A session. 💡 Tune in here: https://lnkd.in/d2UDFj3v

📣  Neola Medical today released the Q4 report of 2024! 📘👶🏻🫁 – Received approval for initiation of first clinical pilot study on preterm born babies “Having achieved key milestones in 2024, we now enter the clinical phase with approval to initiate the first clinical study with Neola® on preterm born babies in neonatal care”, says CEO Hanna Sjöström 💡 Read the entire press release and the report at our website: https://lnkd.in/dPryiAgK 🎥 Don’t miss when CEO Hanna Sjöström and CFO David Folkesson presents the Q4 report today at 11 am (CET). Watch the presentation here: https://lnkd.in/d9fVJnVZ

📣 Neola Medical receives approval by Swedish Authorities to initiate Clinical Pilot Study on Preterm Born Babies in Sweden 🇸🇪 “This study marks a milestone as the first evaluation of Neola® in its target patient population, preterm born babies, underscoring our commitment to improving neonatal care. Securing approval for clinical studies in this vulnerable population is a rigorous process, highlighting the company’s ability to navigate stringent regulatory requirements”, says CEO Hanna Sjöström. 💡Read more in the press release here: https://lnkd.in/dpDT-Jc9

📣 We hereby invite you to presentation of our Q4 report of 2024! The report presentation will be held online as a webcast hosted by Finwire. The Q4-report will be published the same day in the morning. 🗓️ February 12, 2025, at 11:00 CET (11.00) 🎥 Watch the presentation here: https://lnkd.in/d9fVJnVZ where you also can type in questions in advance and during the presentation that we will be answering live during the Q&A after the presentation. 📨 💡Read more in the press release here: https://lnkd.in/dCuXU_wX

📣 Nomination Committee Appointed at Neola Medical 💡 Read the entire press release in Swedish here: https://lnkd.in/dgrzfxx7

🇺🇸 CEO Hanna Sjöström on site at the J.P. Morgan Healthcare Conference in San Francisco, sharing updates on Neola Medical’s commitment toward transforming neonatal care 👶🫁🌟

📣 Neola Medical to Participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco "The J.P. Morgan Healthcare Conference offers an invaluable opportunity to strengthen Neola Medical’s position as we advance toward commercialization. This event allows us to showcase our progress, forge meaningful partnerships, and align with key stakeholders who are essential to our U.S. market entry and scaling efforts.” says CEO Hanna Sjöström 💡Read the entire press release here: https://lnkd.in/dMbu6DHR

📣 Today we released the Winter edition of Neola Medical’s Investor Letter, where CEO Hanna Sjöström highlights a year of significant advancements “In 2024, we reached two significant milestones that are essential for our upcoming FDA application: securing the CB certificate and successfully completing the Human Factors Validation study with nurses in the U.S. These accomplishments mark our transition from the technical verification to the clinical validation phase, preparing for our first clinical study on preterm born babies with our continuous lung monitoring device, Neola®.”, says CEO Hanna Sjöström 💡 Read the entire press release and the investor letter here: https://lnkd.in/dB8sH9U9